Testosterone Formulations: Titration & Tapering Algorithms

Is there a testosterone tapering algorithm?

The injectable labels do not contain a tapering schedule. The Depo-Testosterone dosing section says the dose is adjusted according to the patient's response and the appearance of adverse reactions [1]. The generic enanthate label says dosage and duration depend on age, sex, diagnosis, response to treatment and adverse effects, that total doses above 400 mg per month are not required, and that injections more often than every two weeks are rarely indicated [2]. Neither describes a step-down sequence. If a venous thromboembolic event is suspected, both labels say to discontinue testosterone and begin appropriate workup and management [1][2].

How the injectable labels set up titration

Both labels require the diagnosis to be confirmed before the first dose: serum testosterone measured in the morning on at least two separate days, with both values below the normal range [1][2].

Depo-Testosterone is given deep in the gluteal muscle, intramuscularly only, and never intravenously [1]. The enanthate label says to inject slowly and deeply into the gluteal muscle, avoiding intravascular injection [2]. Replacement dosing is the same range on both labels: 50 to 400 mg every 2 to 4 weeks [1][2].

Cypionate and enanthate are esters of testosterone in oil. Injected into muscle, they are absorbed slowly from the lipid phase [1]. The cypionate label gives about eight days as the half-life after intramuscular injection [1].

Both labels state that safety and efficacy in men with age-related hypogonadism have not been established [1][2]. FDA asked in June 2026 for that limitation to be removed and for prostate safety information to be revised, but the injectable labels checked still carry the older limitation text [4].

What serum level do dose changes aim for?

The injectable labels tie adjustment to clinical response and adverse reactions rather than to a number [1][2]. The specific numeric target that does appear comes from TRAVERSE, the large cardiovascular safety trial, in which the dose of 1.62% testosterone gel was adjusted to keep serum testosterone between 350 and 750 ng/dL [5]. That target was set for a topical gel, not for an injection.

Monitoring that accompanies dosing

Hematocrit. Testosterone raises hematocrit, and the size of the rise depends on the formulation. In a network meta-analysis of 29 placebo-controlled trials covering 3,393 men, intramuscular enanthate or cypionate raised mean hematocrit by 4.0% (95% CI 2.9 to 5.1), oral testosterone undecanoate by 4.3%, gel by 3.0%, patch by 1.4% and intramuscular undecanoate by 1.6% [3]. The rise with intramuscular enanthate or cypionate was significantly larger than with the patch [3].

A retrospective single-center review of 178 hypogonadal men followed for three years found erythrocytosis, defined there as hematocrit above 50%, in 66.7% of men on injectable testosterone, 35.1% on pellets and 12.8% on gels. The injection group was younger, with a mean age of 42.5 years, and started with higher hematocrit; the study was not randomized [6]. Reviews describe the erythrocytosis risk as well established, with short-acting injectables having the highest incidence [7], and report a 315% greater risk of hematocrit above 0.52 compared with controls [8]. Polycythemia is listed among the cypionate label's hematologic adverse reactions [1].

Blood pressure. The cypionate and enanthate labels warn that testosterone can increase blood pressure, which can increase cardiovascular risk over time, and say the products are not recommended for men with uncontrolled hypertension [1][2]. FDA says its required ambulatory blood pressure monitoring studies confirmed a blood pressure increase with all testosterone products, class-wide [9].

Prostate. Known or suspected prostate carcinoma is a contraindication to both products [1][2]. The Endocrine Society guideline recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of treatment [10].

What happens when testosterone is stopped?

Exogenous androgens suppress the body's own signalling. During treatment, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone, and at large doses also follicle stimulating hormone, which suppresses sperm production [1]. Oligospermia is listed as an adverse reaction at high doses [1].

The label's withdrawal description applies to people taking more than the prescribed dose: withdrawal symptoms can last for weeks or months and include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism [1]. The label states that drug dependence in people using approved doses for approved indications has not been documented [1].

Fertility after stopping testosterone

The Endocrine Society guideline recommends against starting testosterone therapy in men who plan to have children in the near term [10].

Recovery data come from men who stopped testosterone and were treated with hCG plus another agent. In a retrospective series of 49 men with azoospermia or severe oligospermia while on testosterone, hCG 3,000 units subcutaneously every other day supplemented with clomiphene, tamoxifen, anastrozole or recombinant follicle stimulating hormone produced a return of spermatogenesis or improved counts in 47 men (95.9%), at an average of 4.6 months, with a mean first density of 22.6 million/mL [11].

A second retrospective study of 66 men used testosterone cessation plus high-dose hCG and a selective estrogen receptor modulator: 46 men (70%) reached a total motile count above 5 million within 12 months. Only 64.8% of azoospermic men did, compared with 91.7% of cryptozoospermic men, and older age and longer testosterone use predicted slower recovery [12].

For context on how long hormonal suppression takes to reverse at all, an integrated analysis of 30 studies in 1,549 healthy men using androgen-based contraception found a median of 3.4 months to recover a sperm concentration of 20 million/mL; 67% recovered within 6 months, 90% within 12 months and 100% within 24 months [13]. Those men did not have hypogonadism.

Cardiovascular safety data and label wording

TRAVERSE randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease to daily 1.62% testosterone gel or placebo. The primary composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 7.0% versus 7.3% (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting noninferiority. Mean treatment was 21.7 months and mean follow-up 33 months [5].

FDA responded in February 2025 with class-wide label changes: it recommended adding TRAVERSE results to every testosterone label and removing boxed-warning language about increased cardiovascular risk, and required a blood pressure warning for products that lacked one [9]. The cypionate label still says long-term cardiovascular safety trials have not been conducted, that studies are inconclusive for major adverse cardiovascular events, and that some but not all studies reported an increased risk [1]; the enanthate label carries the same text [2].